- Therapeutics MD press release (NASDAQ:TXMD): FY net loss from continuing operations was $7.7 million, or $0.74 per basic and diluted share, compared to net income from continuing operations of $1.1 million, or $0.12 per basic and $0.11 per diluted share, for 2022.
- Gross license royalties totaled about $4.5M under the Mayne License agreement for the full year ending December 31, 2023.
- As of December 31, 2023, the company’s cash and cash equivalents totaled $4.3 million.
- The company said it continues to evaluate a variety of strategic alternatives that may include, but not be limited to, an acquisition, merger, other business combination, sale of assets, or other strategic transactions involving the company.
Source link
